Literature DB >> 15905569

Role for innate IFNs in determining respiratory syncytial virus immunopathology.

Teresa R Johnson1, Sara E Mertz, Negin Gitiban, Sue Hammond, Robin Legallo, Russell K Durbin, Joan E Durbin.   

Abstract

Respiratory syncytial virus (RSV) is the major cause of severe lower airway disease in infants and young children, but no safe and effective RSV vaccine is yet available. The difficulties involved in RSV vaccine development were recognized in an early vaccine trial, when children immunized with a formalin-inactivated virus preparation experienced enhanced illness after natural infection. Subsequent research in animal models has shown that the vaccine-enhanced disease is mediated at least in part by memory cells producing Th2 cytokines. Previously we had observed enhanced, eosinophilic lung pathology during primary infection of IFN-deficient STAT1(-/-) mice that are incapable of generating Th1 CD4(+) cells. To determine whether these effects depended only on Th2 cytokine secretion or involved other aspects of IFN signaling, we infected a series of 129SvEv knockout mice lacking the IFN-alphabetaR (IFN-alphabetaR(-/-)), the IFN-gammaR (IFN-gammaR(-/-)), or both receptors (IFN-alphabetagammaR(-/-)). Although both the IFN-gammaR(-/-) and the IFN-alphabetagammaR(-/-) animals generated strong Th2 responses to RSV-F protein epitopes, predominantly eosinophilic lung disease was limited to mice lacking both IFNRs. Although the absolute numbers of eosinophils in BAL fluids were similar between the strains, very few CD8(+) T cells could be detected in lungs of IFN-alphabetagammaR(-/-) animals, leaving eosinophils as the predominant leukocyte. Thus, although CD4(+) Th2 cell differentiation is necessary for the development of allergic-type inflammation after infection and appears to be unaffected by type I IFNs, innate IFNs clearly have an important role in determining the nature and severity of RSV disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905569     DOI: 10.4049/jimmunol.174.11.7234

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

Review 1.  Acute and chronic airway responses to viral infection: implications for asthma and chronic obstructive pulmonary disease.

Authors:  Michael J Holtzman; Jeffrey W Tyner; Edy Y Kim; Mindy S Lo; Anand C Patel; Laurie P Shornick; Eugene Agapov; Yong Zhang
Journal:  Proc Am Thorac Soc       Date:  2005

2.  Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections.

Authors:  Markus Mordstein; Eva Neugebauer; Vanessa Ditt; Birthe Jessen; Toni Rieger; Valeria Falcone; Frederic Sorgeloos; Stephan Ehl; Daniel Mayer; Georg Kochs; Martin Schwemmle; Stephan Günther; Christian Drosten; Thomas Michiels; Peter Staeheli
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

3.  Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.

Authors:  Luis Martinez-Sobrido; Negin Gitiban; Ana Fernandez-Sesma; Jerome Cros; Sara E Mertz; Nancy A Jewell; Sue Hammond; Emilio Flano; Russell K Durbin; Adolfo García-Sastre; Joan E Durbin
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 4.  New insights for development of a safe and protective RSV vaccine.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Kari Ann Shirey; Gregory A Prince; Stefanie N Vogel
Journal:  Hum Vaccin       Date:  2010-06-01

5.  The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response.

Authors:  Alexander Kotelkin; Igor M Belyakov; Lijuan Yang; Jay A Berzofsky; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Mucosal inoculation with an attenuated mouse pneumovirus strain protects against virulent challenge in wild type and interferon-gamma receptor deficient mice.

Authors:  John A Ellis; Brittany V Martin; Cheryl Waldner; Kimberly D Dyer; Joseph B Domachowske; Helene F Rosenberg
Journal:  Vaccine       Date:  2006-10-12       Impact factor: 3.641

7.  C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression.

Authors:  Guillermina A Melendi; Scott J Hoffman; Ruth A Karron; Pablo M Irusta; Federico R Laham; Alison Humbles; Brian Schofield; Chien-Hsiung Pan; Richard Rabold; Bhagvanji Thumar; Adeep Thumar; Norma P Gerard; Wayne Mitzner; Scott R Barnum; Craig Gerard; Steven R Kleeberger; Fernando P Polack
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Respiratory syncytial virus differentially activates murine myeloid and plasmacytoid dendritic cells.

Authors:  Ivette Boogaard; Marijke van Oosten; Leonie S van Rijt; Femke Muskens; Tjeerd G Kimman; Bart N Lambrecht; Anne-Marie Buisman
Journal:  Immunology       Date:  2007-04-30       Impact factor: 7.397

9.  SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism.

Authors:  Matthew B Frieman; Jun Chen; Thomas E Morrison; Alan Whitmore; William Funkhouser; Jerrold M Ward; Elaine W Lamirande; Anjeanette Roberts; Mark Heise; Kanta Subbarao; Ralph S Baric
Journal:  PLoS Pathog       Date:  2010-04-08       Impact factor: 6.823

10.  Quantitative proteomic analysis of A549 cells infected with human respiratory syncytial virus.

Authors:  Diane C Munday; Edward Emmott; Rebecca Surtees; Charles-Hugues Lardeau; Weining Wu; W Paul Duprex; Brian K Dove; John N Barr; Julian A Hiscox
Journal:  Mol Cell Proteomics       Date:  2010-07-20       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.